Compare Nomura Holdings Inc (NMR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Revvity Inc — how do they compare? Nomura Holdings Inc trades at $10.84 (market cap $31.31B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Nomura Holdings Inc is far larger — about 2.2× Revvity Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| NMR | RVTY | |
|---|---|---|
Market Cap | $31.31B | $14.18B |
Sector | Financials | Technology |
52-Week High | $10.65 | $130.94 |
52-Week Low | $6.73 | $82.26 |
Dividend Yield | 3.05% | 0.22% |
Enterprise Value | — | $16.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $10.63, down 0.19% on the day, with a bullish technical signal driven by moving averages. Recent earnings show mixed quarterly performance but strong annual growth, with revenue reaching $1.66 trillion in 2025 and net income margin at 20.4%. The stock is supported by positive momentum coverage and a solid ROE of 11.03%.
Outlook remains favorable due to valuation metrics like a P/E of 12.46 and bullish analyst sentiment, though risks include volatile cash flows and rising debt-to-asset ratios. Investment opportunity lies in continued wholesale segment growth and ROE expansion, balanced by execution risks in a competitive financial sector.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
